Skip to main content

VC Investor Launches $125M Life Sciences Fund

NEW YORK (GenomeWeb News) – Excel Venture Management, a venture capital firm based in Boston, announced today that it has launched the Excel Medical Fund with $125 million to be invested in early- to late-stage life science platform companies.

Excel said that the new fund will focus its investments on healthcare information technology, services, diagnostics, medical devices, and life sciences platforms with applicability to adjacent industries such as energy, chemicals, defense, and agriculture.

The new fund also has already established investments in two genomics industry players: BioTrove and Synthetic Genomics.

The investment team for the fund includes Managing Directors Rick Blume, Steven Gullans, Juan Enriquez, and Enrico Petrillo; Venture Partner Donald Crothers; and Vice Presidents Caleb Winder and Tricia Moriarty.

"Excel's portfolio will be balanced across the many interrelated sectors that are impacted by life science technologies," Enriquez said in a statement. "The rapid adoption and expansion of these technologies into major industries such as energy, chemicals, defense, and agriculture represents an enormous investment opportunity. We believe that we are just seeing the tip of the iceberg."

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.